Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220295 · ClinicalTrials.gov registry record · Phase 1
Putative Cognitive Enhancer VU319
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03220295 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 52 participants.
The verdict
NCT03220295, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.
Interventions
- DRUG Single Dose of VU319
- DRUG Single Dose Placebo
- OTHER Fed State
- OTHER Fasted State
- DRUG Dose Escalation of VU319
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220295
The ClinicalTrials.gov registry entry for NCT03220295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Single Dose of VU319 is the first listed.
NCT03220295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220295 about?
NCT03220295 is a clinical study titled "Putative Cognitive Enhancer VU319". This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.
What is the current status of trial NCT03220295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-07-28. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT03220295?
The interventions under investigation include: Single Dose of VU319 (DRUG), Single Dose Placebo (DRUG), Fed State (OTHER), Fasted State (OTHER), Dose Escalation of VU319 (DRUG).
Who is sponsoring clinical trial NCT03220295?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.